Journal of travel medicine
-
Randomized Controlled Trial
Pooled safety evaluation for a new single-shot live-attenuated chikungunya vaccine.
Chikungunya disease, caused by chikungunya virus (CHIKV), is associated with substantial morbidity, including debilitating CHIKV-related arthralgia. ⋯ A single dose of VLA1553 presented with an excellent local tolerability profile and overall safety in line with that expected for a live-attenuated vaccine. The safety profile was comparable in participants aged 18-64 years and ≥65 years.